Literature DB >> 6445225

Chemotherapy programs of the National Prostatic Cancer Project (NPCP).

J D Schmidt, W W Scott, R Gibbons, D E Johnson, G R Prout, S Loening, M Soloway, J B deKernion, J E Pontes, N H Slack, G P Murphy.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6445225

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


× No keyword cloud information.
  14 in total

Review 1.  A history of prostate cancer treatment.

Authors:  Samuel R Denmeade; John T Isaacs
Journal:  Nat Rev Cancer       Date:  2002-05       Impact factor: 60.716

Review 2.  Mitoxantrone. A review of its pharmacology and clinical efficacy in the management of hormone-resistant advanced prostate cancer.

Authors:  L R Wiseman; C M Spencer
Journal:  Drugs Aging       Date:  1997-06       Impact factor: 3.923

3.  Prolonged remission of fulminant castrate-resistant prostate cancer: a case report.

Authors:  Mehmet Asim Bilen; Rosale General; Shi-Ming Tu
Journal:  Clin Genitourin Cancer       Date:  2011-05-14       Impact factor: 2.872

4.  Buserelin treatment of advanced prostatic cancer: a phase II study.

Authors:  A Veronesi; G Lo Re; V Dal Bo; M D Magri; M Della Valentina; R Talamini; A Merlo; M Francini; S Monfardini
Journal:  Med Oncol Tumor Pharmacother       Date:  1989

Review 5.  Prostate cancer: 9. Treatment of advanced disease.

Authors:  M E Gleave; N Bruchovsky; M J Moore; P Venner
Journal:  CMAJ       Date:  1999-01-26       Impact factor: 8.262

6.  Cytostatic therapy, its value and indications in the management of prostatic carcinoma.

Authors:  J Hübler; D Frang
Journal:  Int Urol Nephrol       Date:  1987       Impact factor: 2.370

7.  Combination of long-acting microcapsules of the D-tryptophan-6 analog of luteinizing hormone-releasing hormone with chemotherapy: investigation in the rat prostate cancer model.

Authors:  A V Schally; T W Redding
Journal:  Proc Natl Acad Sci U S A       Date:  1985-04       Impact factor: 11.205

8.  Mitomycin C treatment of advanced, hormone-resistant prostatic carcinoma: a phase II study.

Authors:  A Veronesi; V Dal Bo; G Lo Re; M Della Valentina; U Tirelli; A Merlo; R Talamini; M Francini; S Monfardini
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 9.  Aromatase inhibitors in malignant diseases of aging.

Authors:  D C Johannessen; P E Lønning
Journal:  Drugs Aging       Date:  1992 Nov-Dec       Impact factor: 3.923

10.  Phase II trial and pharmacokinetic assessment of intravenous melphalan in patients with advanced prostate cancer.

Authors:  D C Smith; D I Jodrell; M J Egorin; R M Ambinder; E G Zuhowski; W Kreis; P G Ellis; D L Trump
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.